The researchers administered intratumoral glucocorticoid receptor KO anti-IL13Rα2 CAR T cells plus systemic glucocorticoids and aldesleukin in six patients with progressive/recurrent grade III or IV glioblastoma [214]. Here, IL13RA2 is linked to glioblastoma.